Title:
NEW COMPOUND FOR INHIBITING BINDING BETWEEN DX2 PROTEIN AND P14/ARF PROTEIN, AND PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CANCER DISEASE CONTAINING SAME AS EFFECTIVE INGREDIENT
Document Type and Number:
WIPO Patent Application WO/2016/003158
Kind Code:
A2
Abstract:
The present invention relates to a new compound for inhibiting binding between a DX2 protein and a p14/ARF protein, and a medical use thereof. A review of the in vitro and in vivo anticancer effect of the compound shows that the compound has an excellent anticancer effect and thus is useful as a drug for treating various cancer diseases including lung cancer, and has a more improved anticancer effect particularly by inhibiting resistance to an anticancer drug of Adriamycin in a cell line which is resistant to an anticancer drug such as Adriamycin, and thus can be used as an anticancer adjuvant for improving the anticancer effect. In addition, the present invention relates to a composition for diagnosing lung cancer comprising an AIMP2-DX2 protein or a fragment thereof, and is effective in diagnosis of lung cancer because whether or not a subject has lung cancer is confirmed only by using a serum sample of the subject.
Inventors:
PARK BUM JOON (KR)
SONG GYU YONG (KR)
OH AH-YOUNG (KR)
LEE JEE-HYUN (KR)
HER JIN-HYUK (KR)
SONG GYU YONG (KR)
OH AH-YOUNG (KR)
LEE JEE-HYUN (KR)
HER JIN-HYUK (KR)
Application Number:
PCT/KR2015/006701
Publication Date:
January 07, 2016
Filing Date:
June 30, 2015
Export Citation:
Assignee:
PUSAN NAT UNIV IND COOP FOUND (KR)
IAC IN NAT UNIV CHUNGNAM (KR)
IAC IN NAT UNIV CHUNGNAM (KR)
International Classes:
C07D407/12; A61K31/34; A61K31/35; A61K31/352; A61P35/00; C07D493/04; C12Q1/68; G01N33/574
Other References:
See references of EP 3162803A4
Attorney, Agent or Firm:
TAEBAEK INTELLECTUAL PROPERTY LAW FIRM (KR)
특허법인 태백 (KR)
특허법인 태백 (KR)
Download PDF: